acf70af7-cea9-4620-82c1-d488e7dab8d0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.440
- E2F_TARGETS+0.390
- INTERFERON_GAMMA_RESPONSE+0.360
- OXIDATIVE_PHOSPHORYLATION+0.340
- MYC_TARGETS_V1+0.250
- MYC_TARGETS_V2+0.250
- G2M_CHECKPOINT+0.230
- ALLOGRAFT_REJECTION+0.210
- INFLAMMATORY_RESPONSE+0.190
- PEROXISOME+0.190
Top 10 suppressed
- ANGIOGENESIS-0.470
- HEDGEHOG_SIGNALING-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- MYOGENESIS-0.380
- APICAL_JUNCTION-0.370
- WNT_BETA_CATENIN_SIGNALING-0.300
- MITOTIC_SPINDLE-0.280
- PROTEIN_SECRETION-0.250
- ESTROGEN_RESPONSE_EARLY-0.210
- HYPOXIA-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-KU-A6H7-01A-11R-A31N-07 | — | — | 0.863 |
| 2 | bd9c63e1-a1cb-4b2f-a909-839ce2fd8618 | — | — | 0.848 |
| 3 | TCGA-CV-6433-01A-11R-1686-07 | — | — | 0.806 |
| 4 | SRR8518222 | — | D | 0.789 |
| 5 | TCGA-CN-A6UY-01A-12R-A34R-07 | — | — | 0.788 |
| 6 | 20080227.Her2HRpos | — | C | 0.785 |
| 7 | TCGA-TN-A7HL-01A-11R-A34R-07 | — | — | 0.784 |
| 8 | TCGA-D8-A1XL-01A-11R-A14M-07 | — | B | 0.783 |
| 9 | C3N-00579 | — | cohortA1 | 0.783 |
| 10 | MNG171 | — | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.250 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.020 | Idelalisib | — uncovered |